CMPX
Compass Therapeutics, Inc.Healthcare·Biotechnology
$2.38
$329M market cap
Revenue
$0.0M
Free Cash Flow
$-30.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody
2-Year Price History
$2.07+46.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -19.9 | -20.3 | -18.3 | -17.3 | -17.4 | -0.1 | 194.7 | 9.8 | 186.4 | -130.1% | -- | -- |
| Act | 2025-Q4 | 0.0 | -17.6 | -18.0 | -15.7 | -13.3 | -13.3 | -0.0 | 208.9 | 9.8 | 184.8 | -97.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$2.38
Market Cap$329M
Enterprise Value$144M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-9.3%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-34.0M
Free Cash Flow$-30.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-113.8%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares30.4M
Days to Cover1.4
Change (vs Prior)+16.7%
Need at least 2 settlement dates for chart
Employees
Headcount35
Revenue / Employee$0
Gross Profit / Employee$-21,086
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
282.2%(+218.4% YoY)
178 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
58.5%(+46.3% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
1.6%(+0.7% YoY)
9 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | $88.8M | $2.20 | +$0 | +$30.4M | -5.7% | $1.93B |
| ORBIMED ADVISORS LLC | $80.5M | $3.98 | +$0 | −$37.8M | -8.2% | $4.38B |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $75.7M | $3.08 | +$661K | +$75.7M | -9.1% | $3.69B |
| Vivo Capital, LLC | $50.5M | $3.52 | +$0 | +$31.7M | -7.0% | $1.20B |
| BlackRock, Inc.Passive | $50.3M | $2.73 | +$621K | +$12.7M | -0.2% | $5.69T |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $44.9M | $3.33 | +$21.4M | +$23.9M | -0.1% | $64.61B |
| Enavate Sciences GP, LLC | $41.2M | $1.45 | +$0 | +$0 | +8.3% | $352M |
| BVF INC/IL | $41.1M | $4.23 | +$0 | +$41.1M | -0.4% | $3.14B |
| STATE STREET CORPPassive | $35.4M | $4.41 | +$9.5M | +$25.1M | -0.2% | $2.89T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $31.9M | $5.29 | +$31.9M | +$31.9M | — | $4.04T |
| RTW INVESTMENTS, LP | $22.1M | $4.22 | +$8.9M | +$22.1M | -2.2% | $9.26B |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $19.1M | $5.37 | +$0 | +$19.1M | -0.8% | $7.18B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $18.9M | $3.31 | +$335K | +$6.4M | +2.3% | $1.61T |
| Rock Springs Capital Management LP | $17.5M | $2.29 | −$3.3M | −$8.8M | -2.0% | $1.65B |
| Logos Global Management LP | $16.7M | $4.38 | +$10.6M | +$16.7M | -1.6% | $1.94B |
| Blue Owl Capital Holdings LP | $15.6M | $2.43 | −$2.8M | −$70K | -2.4% | $372M |
| Qube Research & Technologies Ltd | $13.5M | $5.22 | +$11.2M | +$13.5M | +0.3% | $70.36B |
| UBS Group AG | $12.7M | $4.89 | +$11.8M | +$11.8M | -0.3% | $562.11B |
| Sofinnova Investments, Inc. | $10.9M | $4.24 | −$6.9M | +$10.9M | +2.6% | $1.94B |
| GOLDMAN SACHS GROUP INC | $10.6M | $3.90 | +$2.5M | +$9.3M | -0.2% | $760.93B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-2.30%
avg per quarter
Holders (ex-self)
-2.42%
excl. this stock
Buyers (this Q)
-0.33%
115 buyers · $0.19B in
Sellers (this Q)
+0.58%
49 sellers · $0.09B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+13.3%
how holders react when this stock falls
On quiet Qs
-6.1%
−10% to +10% baseline
On rallies (+10%+)
-9.7%
how they react when this stock rises
Holders' portfolio flow this Q
-5.1%
outflows — trims may be forced
Sellers' portfolio flow this Q
-7.2%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.1%
Holder mid (any stock)
-3.8%
Holder rally (any stock)
-6.0%
Biggest decreases this quarter
Blackstone Group L.P.−$22.6Mα+2.9Trails Edge Capital Partners, LPexited−$7.6MSofinnova Investments, Inc.−$6.9Mα+2.6MARSHALL WACE, LLPexited−$6.8MBRAIDWELL LP−$4.3Mα-1.7FMR LLC−$4.1Mα-0.0Rock Springs Capital Management LP−$3.3Mα-2.0HealthInvest Partners ABexited−$3.1MBlue Owl Capital Holdings LP−$2.8Mα-2.4HighVista Strategies LLCexited−$1.3M
New buyers this quarter
Top-5 holders · 37.7%
TANG CAPITAL MANAGEMENT LLC--
ORBIMED ADVISORS LLC--
SUVRETTA CAPITAL MANAGEMENT, LLC--
Vivo Capital, LLC--
BlackRock, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
ORBIMED ADVISORS LLC15.2MTANG CAPITAL MANAGEMENT LLC16.8MSUVRETTA CAPITAL MANAGEMENT, LLC14.3MVivo Capital, LLC9.5MADAGE CAPITAL PARTNERS GP, L.L.C.8.5MEnavate Sciences GP, LLC7.8MBVF INC/IL7.8MBlackstone Group L.P.1.9MFMR LLC1.8MJANUS HENDERSON GROUP PLC56K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | 3 | 173.78× |
| AVBP | ArriVent BioPharma, Inc. Common Stock | 3 | 159.30× |
| OCUL | Ocular Therapeutix, Inc. | 3 | 136.54× |
| TNGX | Tango Therapeutics, Inc. | 3 | 127.44× |
| PTGX | Protagonist Therapeutics, Inc. | 3 | 119.47× |
| ERAS | Erasca, Inc. | 3 | 106.20× |
| GPCR | Structure Therapeutics Inc. | 3 | 106.20× |
| TERN | Terns Pharmaceuticals, Inc. | 4 | 62.17× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$9.0027820.0%
Last Year (6 analysts)$11.0036220.0%
Current Price$2.38
Analyst Ratings
15
Buy: 15Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$97K
3 txns · 3 insiders · 50,000 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-29 | BUY | Anderman Jonathan | officer: General Counsel | 25,000 | $1.89 | $47K | $370K |
| 2026-04-29 | BUY | Lerner Neil | officer: Chief Accounting Officer | 15,000 | $1.89 | $28K | $751K |
| 2025-05-27 | BUY | Schuetz Thomas J. | director, officer: CHIEF EXECUTIVE OFFICER | 10,000 | $2.11 | $21K | $13.67M |
Order Flow (FINRA, ~3w lag)
28.0%retail+1.3pp
20.8%dark+0.6pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Compass Therapeutics, Inc.: A Milestone-Dependent Cash Burner with Embedded Dilution Engines
Overall Risk
5/10
Fraud
2/10
Dilution
9/10
Insolvency
3/10
Earnings Overstated
2/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
2/10
Hidden Upside
4/10
Contextually Acceptable
8/10